Purchase this article with an account.
Byung Ju Jung, Won Ki Lee; Nine-year treatment outcome of naïve polypoidal choroidal vasculopathy in clinical practice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2403. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the nine-year treatment outcomes of naïve polypoidal choroidal vasculopathy (PCV)
Fourty-seven treatment-naïve PCV eyes were reviewed retrospectively. Initial treatment was photodynamic therapy (PDT) alone or PDT combined with anti-vascular endothelial growth factor (VEGF), and adjuvant anti-VEGF or PDT was applied based on recurrence or retreatment criteria. The main outcome measures were best-corrected visual acuity (BCVA) and number of anti-VEGF injections at each year. We also conducted the distribution of BCVA into 3 groups: improved BCVA≥0.3 logMAR, deteriorated BCVA≥0.3 logMAR, and stable BCVA. Furthermore, we divided in 3 groups regarding as the number of PDT sessions: group A (PDT=1), group B (PDT=2), and group C (PDT≥3).
The total mean±SD logMAR BCVA at baseline and year 1, 2, and 9 were 0.49±0.32, 0.30±0.29, 0.38±0.38 and 0.63±0.47, respectively. Significant improvements were observed at year 1 and 2 compared with baseline mean BCVA (p<.001, p =.046, respectively). The means of BCVA change at year 9 were improvement of 0.15 logMAR in the group A, decline of 0.23 logMAR in the group B, and decline of 0.46 logMAR in the group C (p<.001). The total mean number of injections during 9 years were 21.6±14.3 in total, 16.1±9.8 in the group A, 21.9±11.0 in the group B, and 29.0±19.1 in the group C (p=.04). The percentages of improved or stable eye at ninth year were 61.7% in total, 78.9% in the group A, 57.1% in the group B, and 42.8% in the group C (p =.01). 93.6% showed recurrence for the follow-up periods.
Although most PCV eyes experienced recurrence, nine-year prognosis of well treated PCV showed favorable visual outcomes. PDT is a good treatment option, but minimizing a total number of PDT sessions is important for final outcomes.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only